| 发明名称 |
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR |
| 摘要 |
The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus. |
| 申请公布号 |
US2015071911(A1) |
申请公布日期 |
2015.03.12 |
| 申请号 |
US201414231441 |
申请日期 |
2014.03.31 |
| 申请人 |
ROCHE GLYCART AG |
发明人 |
HERTING FRANK;KLEIN CHRISTIAN |
| 分类号 |
C07K14/705;A61K31/436;A61K45/06;A61K39/395 |
主分类号 |
C07K14/705 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. Use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less, for the manufacture of a medicament for the treatment of cancer in combination with a mTOR inhibitor. |
| 地址 |
SCHLIEREN CH |
